NCT05001022View on ClinicalTrials.gov

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 25, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Chronic Hepatitis B
Interventions
DRUG

ALG-020572

Single or multiple doses of ALG-020572

DRUG

Placebo

Single or multiple doses of Placebo

Trial Locations (3)

Unknown

Auckland Clinical Studies, Auckland

King's College Hospital, London

St George's University of London, London

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects | Biotech Hunter | Biotech Hunter